• 🌎 Worldwide
    • πŸ‡ΊπŸ‡Έ U.S.
    • πŸ‡¨πŸ‡¦ Canada
    • πŸ‡¬πŸ‡§ United Kingdom
    • 🌏 Asia
    • 🌍 Europe
    • 🌎 Latin America
    • 🌏 Oceania and Australasia
The Daily Marijuana Observer
SUBSCRIBE
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
No Result
View All Result
Home Investments Press Releases

InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak

Canada Newswire by Canada Newswire
March 20, 2020
in Canada, Investments, Marijuana Stocks, Press Releases
COVID-19 Preparedness News

Image by Diese lizenzfreien Fotos darfst du zwar verwenden from Pixabay

57
SHARES
ShareShare

VANCOUVER, March 20, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today provided an update on the impact of the global outbreak of COVID-19 on its business operations.

In early March, the Company began to implement guidelines of its Pandemic Preparedness Plan, including cancelling all corporate travel, exercising social distancing in the workplace and enabling all staff to work from home. The Company also began to interact on a more frequent basis with the numerous research vendors for all research and development programs to monitor their local situation with regards to the COVID-19 outbreak.

Eric A. Adams, CEO of InMed stated, “In response to the outbreak of COVID-19, InMed is taking all necessary measures to ensure, first and foremost, the health and safety of our employees while also minimizing the impact to our ongoing operations. We are closely monitoring all program activities with our numerous contract research organizations (“CROs”) on a daily basis. We are fortunate that our administrative, scientific and clinical teams are able to operate effectively while working remotely. We are committed to doing everything within our power to limit the possible negative effects on our long-term success.”

In regards to InMed’s INM-755 program, investigating CBN cream as a topical therapy to treat epidermolysis bullosa, the Company has been in regular communications with the Center for Health and Drug Research in the Netherlands, which is the clinical site conducting the 755-101-HV Phase 1 trial. As this trial is nearing completion, InMed does not anticipate a significant disruption in the remaining treatments and collection of data. The Company is diligently preparing for the second healthy volunteer trial, Study 755-102-HV, at the same clinical site, scheduled to begin enrollment in mid-May. The ability to initiate enrollment according to the planned timeline will be assessed at a later date.

The INM-088 program remains on track. The Company anticipates being in a position to select an appropriate delivery formulation for INM-088 in the near term and continues to make plans for advanced preclinical testing in the Spring. The timelines to execute on this study will be determined by both the choice of the delivery formulation (i.e. an internal candidate vs. an external candidate) as well as the availability of the European CRO, in line with their current policies and working status during the pandemic.

Development activities with the Company’s biosynthesis manufacturing platform have not seen any negative impacts due to the outbreak.

Adams continued, “InMed’s executive team is proactively reviewing all expenditures in light of the continued uncertainty around the severity and duration of the virus spread and it is reasonable to expect some impact on our programs over time. We will be in a better position to provide guidance on any changes to development timelines during the next quarterly update teleconference in May.”

About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. Preclinical data demonstrate that INM-755 may help relieve hallmark EB symptoms, such as inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: leading the way in the clinical development of cannabinol (CBN); developing a pipeline of cannabinoid-based medications in diseases with high unmet medical need; ensuring the health and safety of our employees; being able to minimize the impact of COVID-19 on our operations; anticipating no significant disruption in the remaining treatments and collection of data the 755-101-HV phase 1 trial; the potential for some impact on our programs due to the outbreak of COVID-19; limiting possible negative effects on the Company’s long-term success due to the outbreak of COVID-19; being able to begin enrollment of the Study 755-102-HV trial in mid-May; being in a position to select an appropriate delivery formulation for INM-088 in the near term; commencing advanced preclinical testing of INM-088 in the Spring; being in a better position to provide guidance on any changes to development timelines during the next quarterly update teleconference in May; INM-755’s ability to treat epidermolysis bullosa (EB) and potentially other dermatological diseases; and IMN-755 being able to potentially relieve EB symptoms, such as inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; the ability to contract with suitable partners; demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: the outbreak and impact of COVID-19 may worsen; preclinical and clinical testing may not produce the desired results on a timely basis, or at all; regulatory applications may not be approved on a timely basis, or at all; cannabis licensing/importing issues may delay our projected development timelines; suitable partners may not be located; economic or market conditions may worsen; our existing cash runway may not allow us to complete our forthcoming significant milestones; the development of a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical need may not be as successful as desired, if at all. A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at http://www.sedar.com.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Share this:

  • Click to email this to a friend (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)
Tags: biotechcoronavirusCOVID-19InMed Pharmaceuticals Inc.OTC:IMLFFTSX:IN

Get Real-Time Updates from MJobserver.com

Unsubscribe
Canada Newswire

Canada Newswire

Powered by CNW, Cision provides simultaneous distribution of news releases and multimedia to media and financial markets and feeds websites as well as social media accounts and blogs. Our expertise in content distribution has made us a trusted and integral part of the Canadian media and market landscapes. As market leader, Cision is the first place journalists and investors look for news releases from Canadian organizations, and it is the only service commercially endorsed by the TSX for newswire and financial webcast capabilities.

Related Posts

Epidiolex from GW Pharmaceuticals
Investments

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader

February 3, 2021
Epidiolex from GW Pharmaceuticals
Investments

Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community

October 21, 2020
Epidiolex from GW Pharmaceuticals
Executives

GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors

September 10, 2020
Marinol Dronabinol THC Pharmaceutical
Events

30+ Expert Speakers to Present at the 3rd Annual Cannabinoid-Derived Pharmaceuticals Summit

July 9, 2020
Health Canada Licensed Cannabis Producer and Processor Stocks
Press Releases

Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License

June 18, 2020
Sanitizing and Disinfecting Spray
Business

Emerald Organic Products Launches Emerald Shieldβ„’ Division Alongside Nationwide Reopening and β€˜Second Wave’ of Coronavirus

June 18, 2020
Load More
Next Post
Auxly Announces Termination of FSD Pharma Joint Venture - Marijuana Stocks News

Auxly Announces Leadership Changes

Leave a Comment! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

🚨 Subscribe to Stock Alerts

Get Live Updates on Breaking News

Subscribe Now

βœ‰οΈ Subscribe to Our Newsletter!

* indicates required

πŸ”Ž Search Marijuana Stocks

πŸ“° Recent News

  • Verano Holdings Enters into Agreement to Expand Arizona Footprint
  • Green Thumb Industries Announces Initial Public Offering in the U.S. to Raise US$100,000,000
  • Greenlane Announces Dismissal of Remaining Securities Class Action
  • Indiva Reports Record Market Share for January 2021
  • Acreage Announces Fourth Quarter And Full Year 2020 Earnings Date
Facebook Twitter Instagram LinkedIn Youtube

Cannabis News by Region

  • πŸ‡ΊπŸ‡Έ United States
  • πŸ‡¨πŸ‡¦ Canada
  • πŸ‡¬πŸ‡§ United Kingdom
  • 🌏 Asia
  • 🌍 Europe
  • 🌎 Latin America
  • 🌏 Oceania and Australasia

Cannabis Tools & Resources

  • πŸ“… Calendar
  • πŸ“Š Databases
  • πŸ“‡ Directories
  • πŸ”” RSS Feeds
  • πŸ“Ί Videos

Find Cannabis Business Services

  • βš–οΈ Attorneys & Law Firms
  • πŸ“Š Accountants & Accounting Firms
  • πŸ’‘ Consultants & Consulting Firms
  • πŸ“² Marketing Agencies & Firms

The Daily Marijuana Observer

  • Subscribe
  • About MJobserver.com
  • Affiliate Marketing Disclosure
  • Legal Disclaimer
  • Privacy Policy
  • Contact Us

Advertise with Us

  • πŸ‘€ Advertise
  • πŸ“£ DMO Newswire
  • πŸ“‡ List in Our Databases

Β© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observerβ„’ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

No Result
View All Result
  • Home
  • Latest
  • πŸ”’ PRO
    • πŸ”’ A.M. Watchlist
    • πŸ”’ Analyst Action
  • πŸ’Ό Business
  • πŸ“ˆ Investments
    • πŸ“ˆ Stocks
    • πŸ’° ETFs and Funds
    • πŸ’­ Market Commentary
    • πŸ“° Press Releases
    • πŸ“… Earnings Calendar
  • βš–οΈ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • πŸ‘₯ People
    • ⚽ Athletes
    • πŸ’Ό Executives
    • 🌟 Celebrities
    • πŸ›’ Consumers
    • βš•οΈ Doctors
    • πŸ’Š Patients
  • πŸ’Š Health
  • πŸ“‡ Databases
    • πŸ“ˆ Stock Databases
    • πŸ’° Fund Databases
    • πŸ’Ό Service Providers Databases
    • 🏦 Marijuana Stock Brokers
    • πŸ’² Marijuana Cryptocurrencies

Β© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observerβ„’ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.